Evaluation of endometrium by transvaginal ultrasonography and Doppler in tamoxifen-treated women with breast cancer

Purpose: The purpose of this study was to investigate the discriminative role of transvaginal ultrasonography and Doppler measurements on the detection of endometrial pathologies in tamoxifen-treated breast cancer patients. Methods: Tamoxifen-treated breast cancer patients were included in this prospective study between February 2009 and June 2010. The subjects were assessed by gynecologic examination and transvaginal gray-scale and Doppler sonography. The patients whose endometrial thicknesses were more than 6 mm underwent endocervical/endometrial curettage for histopathological examination. Results: There were 98 tamoxifen-treated patients with breast cancer enrolled in the study, providing 141 ultrasound evaluations. Uterine artery pulsatility index was significantly lower in postmenopausal than premenopausal patients (p: 0.013). Endocervical and endometrial curettage was performed in 52 patients. It was more prevalent that the endometrial strip was >= 6 mm in women with abnormal endometrial histopathology (p: 0.020). However the women with abnormal endometrial histopathology presented lower vascular indices; the only significant difference was in myometrial pulsatility index (p: 0.036). Conclusion: The most evident tool for evaluating the endometrium in tamoxifen-treated breast cancer patients is still the transvaginal measurement of its thickness. It exists that Doppler ultrasonographic assessment of uterine, radial and spiral vasculature has no additional benefit for detection of endometrial pathology.

Doppler ultrasonography; Endometrial thickness; Tamoxifen; Transvaginal ultrasonography

[1] Cohen I.: “Endometrial pathologies associated with postmenopausal tamoxifen treatment”. Gynecol. Oncol., 2004, 94, 256.

[2] Senkus-Konefka E., Konefka T., Jassen J.: “The effects of tamoxifen on the female genital tract”. Cancer Treat. Rev., 2004, 30, 291.

[3] ACOG committee opinion. No. 336: “Tamoxifen and uterine cancer. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice”. Obstet. Gynecol., 2006, 10, 1475.

[4] Garuti G., Grossi F., Centinaio G., Sita G., Nalli G., Luerti M.: “Pretreatment and prospective assessment of endometrium in menopausal women taking tamoxifen for breast cancer”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2007, 132, 101.

[5] Markovitch O., Teper R., Aviram R., Fishman A., Shapira J., Cohen I.: “The value of sonohysterography in the prediction of endometrial pathologies in asymptomatic postmenopausal breast cancer tamoxifen-treated patients”. Gynecol. Oncol., 2004, 94, 754.

[6] Develioglu O.H., Omak M., Bilgin T., Esmer A., Tüfekçi M.: “The endometrium in asymptomatic breast cancer patients on tamoxifen: value of transvaginal ultrasonography with saline infusion and Doppler flow”. Gynecol. Oncol., 2004, 93, 328.

[7] Fung M.F., Reid A., Faught W., Le T., Chenier C., Verma S. et al.: “Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen”. Gynecol. Oncol., 2003, 91, 154.

[8] Develioglu O.H., Bilgin T., Yalçın O.T., Özalp S.: “Transvaginal ultrasonography and uterine artery doppler in of diagnosis endometrial pathologies and carcinoma in postmenopausal bleeding”. Arch. Gynecol. Obstet., 2003, 268, 175.

[9] Opolskiene G., Sladkevicius P., Valentin L.: “Ultrasound assessment of endometrial morphology and vascularity to predict endometrial malignancy in women with postmenopausal bleeding and sonographic endometrial thickness > or = 4.5 mm”. Ultrasound. Obstet. Gynecol., 2007, 30, 332.

[10] Epstein E., Valentin L.: “Gray-scale ultrasound morphology in the presence or absence of intrauterine fluid and vascularity as assessed by color Doppler for discrimination between benign and malignant endometrium in women with postmenopausal bleeding”. Ultrasound. Obstet. Gynecol., 2006, 28, 89.

[11] Kedar R.P., Bourne T.H., Powles T.J., Collins W.P., Asley S.E., Cosgrave D.O. et al.: “Effects of Tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial”. Lancet, 1994, 343, 1318.

[12] Timmerman D., Vergutus J., Konstantinovic M.L., Moerman P., Van Schoubroeck D., Deprest J. et al.: “The pedicle artery sign based on sonography wih color Doppler imaging can replace second-stage tests in women with abnormal vaginal bleeding”. Ultrasound Obstet. Gynecol., 2003, 22, 166.

[13] Marconi D., Exacoustos C., Cangi B., Perroni A., Zupi E., Vali E. et al.: “Transvaginal sonographic and hysteroscopic findings in postmenopausal women receiving Tamoxifen”. J. Am. Assoc. Gynecol. Laparosc., 1997, 4, 331.

[14] Cohen I., Beyth Y., Teper R.: “The role of ultrasound in the detection of endometrial pathologies in asymptomatic postmenopausal breast cancer patients with Tamoxifen treatment”. Obstet. Gynecol. Surv., 1998, 53, 429.

[15] Exacoustos C., Zupi E., Cangi B., Chiaretti M., Arduini D., Romanini C.: “Endometrial evaluation in postmenopausal breast cancer patients receiving Tamoxifen: an ultrasound, color flow Doppler, hysteroscopic and histological study”. Ultrasound. Obstet. Gynecol., 1995, 6, 435.